Skip to main content
OpenTrials
Completed

NCT Number: NCT00978653

The Effect of Uric Acid Decrement on Endothelial Function in Patients With Chronic Renal Failure

In this prospective study, the investigators aimed to evaluate the effects of improved hyperuricemia, a minor cardiovascular risk factor, on endothelial dysfunction in patients with chronic kidney disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hyperuricemia Chronic Disease Chronic Kidney Disease Disease Attributes Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Male Urogenital Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency Renal Insufficiency, Chronic Urogenital Diseases Urologic Diseases

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Istanbul Faculty of Medicine

Istanbul, 34390, Turkey (Türkiye)

About this study

Endothelial dysfunction (ED) is a key event in the development of atherosclerotic cardiovascular disease observed in patients with chronic kidney disease (CKD). Experimental models have shown that hyperuricemia causes hypertension and renin angiotensin system activation. In this prospective study, the investigators aimed to evaluate the effects of improved hyperuricemia, a minor cardiovascular risk factor, on ED in patients with CKD.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Laboratory finding of hyperuricemia
  • Patients between ages of 18 and 60 years
  • Non-diabetic patients
  • Creatinine clearance values between 20 and 60 mL/min/1.73 m2

Exclusion criteria

  • Low (< 20 ml/min/1.73 m2) creatinine clearance,
  • Patients with diabetes mellitus, ischemic heart disease, acute coronary syndrome, congestive heart failure (CHF) (New York Heart Association class II or greater), valvular heart disease and a history of cerebral infarction or transient ischemic attack.
  • Patients taking urate lowering medication (allopurinol and probenecid)

Treatment and study plan

Allopurinol

Drug

150 mg once a day

Other names: urikoliz

Primary outcomes

  1. Endothelial function improvement with uric acid lowering treatment

    Time frame: 1 year

Sponsors and collaborators

Lead sponsor

Istanbul University

Other

Registry information

Official study title

Prospective Study of Allopurinol Treatment That Improves Endothelial Function by Decreasing Uric Acid Levels of Patients With Chronic Kidney Disease

Important dates

Study start
2008
Primary completion
2009
Study completion
2009
First posted
Sep 17, 2009
Registry last updated
Sep 22, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.